Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Targeted antitumour therapy--future perspectives.

M Ranson1, G Jayson

  • 1Department of Medical Oncology, University of Manchester, Christie Hospital NHS Trust, Wilmslow Road, Manchester M20 4BX, UK. malcolm.ranson@man.ac.uk

British Journal of Cancer
|June 2, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Enhancing pancreatic cancer immunotherapy: Leveraging localized delivery strategies through the use of implantable devices and scaffolds.

Journal of controlled release : official journal of the Controlled Release Society·2024
Same author

SerpinB2 regulates stromal remodelling and local invasion in pancreatic cancer.

Oncogene·2017
Same author

A phase I, pharmacokinetic and pharmacodynamic study of GSK2256098, a focal adhesion kinase inhibitor, in patients with advanced solid tumors.

Annals of oncology : official journal of the European Society for Medical Oncology·2016
Same author

A phase I, dose escalation, pharmacodynamic, pharmacokinetic, and food-effect study of α2 integrin inhibitor E7820 in patients with advanced solid tumors.

Investigational new drugs·2016
Same author

AZD3514, an oral selective androgen receptor down-regulator in patients with castration-resistant prostate cancer - results of two parallel first-in-human phase I studies.

Investigational new drugs·2015
Same author

Accessing cancer services in North West England: the Chinese population.

European journal of cancer care·2014
Same journal

Oligometastatic neuroendocrine tumors: characteristics and prognosis.

British journal of cancer·2026
Same journal

The concept of functional cure in advanced/metastatic melanoma treated with combined nivolumab and ipilimumab or nivolumab alone.

British journal of cancer·2026
Same journal

Efficacy and safety of a novel oral anti-vasculogenic mimicry agent, CVM-1118, in advanced well-differentiated neuroendocrine tumors: a Phase IIa trial.

British journal of cancer·2026
Same journal

Altretamine induces ferroptosis in small cell lung cancer by promoting epigenetic silencing and lysosomal degradation of GPX4.

British journal of cancer·2026
Same journal

Revisiting retinoic acid in AML therapy: mechanisms of action and rational combination strategies.

British journal of cancer·2026
Same journal

De novo cancer-related mortality after solid organ transplantation in England: the EpCOT study.

British journal of cancer·2026
See all related articles

Targeted therapy offers new cancer treatment avenues. Success hinges on understanding tumor complexity, refining clinical trials, and leveraging advanced technologies for personalized medicine.

Area of Science:

  • Oncology
  • Translational Medicine

Background:

  • Targeted therapy represents a significant advancement in cancer treatment.
  • Translating the promise of targeted agents into clinical benefits remains a challenge.

Purpose of the Study:

  • To outline key factors crucial for the successful clinical implementation of targeted cancer therapies.
  • To emphasize the need for an integrated approach to maximize the efficacy of targeted agents.

Main Methods:

  • Review of current challenges and future directions in targeted cancer therapy.
  • Discussion of the role of tumor microenvironment research, clinical trial design, and technological advancements.

Main Results:

  • Understanding tumor heterogeneity and microenvironment complexity is essential.

Related Experiment Videos

  • Refining clinical trial designs with novel endpoints (e.g., optimal biological dose, quality of life) is necessary.
  • Advancements in proteomics, genomics, and biomarkers are key for predicting treatment response and assessing drug effects.

    • Conclusions:

    • The future success of targeted therapy requires a multidisciplinary, integrated approach.
    • Collaboration among all stakeholders is vital for realizing the full potential of targeted cancer treatments.